Skip to content

Investigation of the Effect of Asvard Capsules on the Adults Reflux

Comparison of the Effectiveness of Asvard and Omeprazole Capsules on the Ameliorating Symptoms in the Adults Gastroesophageal Reflux

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230226057538N1
Enrollment
144
Registered
2023-04-03
Start date
2023-05-10
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux. Gastro-esophageal reflux disease

Interventions

Intervention 1: Intervention group: Treatment with omeprazole capsules 20 mg per day. Intervention 2: Intervention group: Asvard capsule 1200 mg per day (900 cases + 300 roses). Intervention 3: Interv

Sponsors

Gorgan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The Reflux patients with the age between 18-60 years olds. The patients have to been infected with the Reflux disease for 6 months ago and it get shown Reflux symptoms twice in the week. Reflux diagnosis would be base on ROME IV symptoms and endoscopy without specific pathological findings All subjects must be without Helicobacter pylori infection. All subjects don't have been any antibiotics and PPIs in the last month. Without underlying diseases such as heart failure; kidney and liver failure; cirrhosis; Diabetes, thyroid disorders, etc. Without cigarette smoking, drugs abuse or alcohol Without taking NSAIDs or Aspirin Without pregnancy or breastfeeding

Exclusion criteria

Exclusion criteria: If patient use a drug with a direct impact on the digestive system. If patient is infected to underlying diseases.

Design outcomes

Primary

MeasureTime frame
Analysis of Reflux symptoms. Timepoint: Days: zero, 21, 42 and 56. Method of measurement: Questionnaires and standard measurement scales.

Secondary

MeasureTime frame
Investigation of likely side effects after drug administration. Timepoint: Days: 21, 42 and 56. Method of measurement: Visual Analogue Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeid Sepehrikia

Gorgan University of Medical Sciences

dr.sepehrikia@yahoo.com+98 17 3245 1653

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026